Scientific Program - Wednesday 21 February

Print
Please see below the CODHy Scientific Program. Please click on the appropriate day to view the relevant program. To view the program timetable / overview, please click here

 

     
Wednesday 21 February Thursday 22 February, 2018 Friday 23 February, 2018
Wednesday 21 February, 2018
HALL A
09:00-10:30
09:00-09:05
09:00-09:25
09:25-09:45
09:45-10:05
10:05-10:30
PLENARY OPENING SESSION 1 – DIABETES TOMORROW
Chairperson
Pharmacologic therapy: What’s next? Ralph DeFronzo, USA
Precision medicine: Myth or reality? Stefano Del Prato, Italy
Individualization and big data: Synergy or contradiction? Itamar Raz, Israel 
Discussion
10:30-11:00
COFFEE BREAK
HALL A
11:00-12:30
11:00-11:05
11:05-11:20
11:20-11:35
11:35-11:50
11:50-12:05
12:05-12:30
SESSION 2 – IDENTIFYING SUBJECTS AT RISK
Chairperson
To screen or no to screen? Jaako Tuomilheto, Finland
Genes vs. phenotype: Valeriya Lyssenko, Sweden
Cost-effectiveness of prevention: Orly Tamir, Israel
The long-term effect of the environment – Epigenetics: Charlotte Ling, Sweden
Discussion
HALL B
11:00-12:30
11:00-11:05
11:05-11:25
11:25-11:45
11:45-12:05
12:00-12:30
SESSION 3 – TREATMENT INDIVIDUALIZATION
Chairperson
Pharmacogenomics: TBC 
Treatment personalization after the CVO trials: Enzo Bonaro, Italy
Decision support: Are we there? Avivit Cahn, Israel
Discussion
HALL C
11:00-12:30
11:00-11:05
11:05-11:25
11:25-11:45
11:45-12:05
12:00-12:30
SESSION 4 – PREVENTING DIABETIC NEPHROPATHY
Chairperson
Diabetic CKD: An evolving phenotype: Anna Solini, Italy
Incretins: TBC 
SGLT2-inhibitors: Ofri Mosenzen, Israel
Discussion
12:30-13:30
LUNCH
HALL A
13:30-15:00
13:30-13:35
13:35-13:55
13:55-14:15
14:15-14:35
14:35-15:00
SESSION 5 – NEW ANTI-HYPERGLYCEMIC AGENTS AND DIABETES PREVENTION
Chairperson
DPP4-inhibitors: Baptist Gallwitz, Germany
GLP-1 RAS: Agostino Consoli, Italy
SGLT2-inhibitors: John Wilding, UK
Discussion
HALL B
13:30-15:00
13:30-13:35
13:35-13:55
13:55-14:15
14:15-14:35
14:35-15:00
SESSION 6 – TREATMENT INITIATION IN T2DM
Chairperson
The role and meaning of guidelines: Jaime Davidson, USA
Treat-to-goal or pathophysiological driven treatment? Ralph DeFronzo, USA
Patient/physician empowerment: Paolo Pozzilli, Italy
Discussion
HALL C
13:30-15:00
13:30-13:35
13:35-13:55
13:55-14:15
14:15-14:35
14:35-15:00
SESSION 7 – THE ELDERLY T2DM
Chairperson
Obesity and sarcopenia: Stefano Volpato, Italy
How to select anti-hyperglycemic treatment: Antonio Ceriello, Spain
Injectable: Philip Home, UK
Discussion
15:00-15:30
COFFEE BREAK
HALL A
15:30-17:00
15:30-15:35

15:35-15:50
15:50-16:05

16:05-16:20
16:20-16:35
16:35-17:00
SESSION 8 – HYPERTENSION I
Chairperson
Does weight loss effective in lowering BP in the long run?
Yes: Dror Dicker, Israel
No: Ehud Grossman, Israel
Drug treatment of resistant hypertension
Antialdosterone agents: Alon Grossman, Israel
Other Strategies: Anna Solini, Italy
Discussion
HALL B
15:30-17:00
15:30-15:35
15:35-15:55
15:55-16:15
16:15-16:35
16:35-17:00
SESSION 9 – WHAT TO TREAT IN T2DM?
Chairperson
The diabetologist: Apostolos Tsapas, Greece
The cardiologist: Chaim Lotan, Israel
The family physician: Xavier Cos Claramunt, Spain
Discussion
7HALL C
15:30-17:00
15:30-15:35
15:35-15:55
15:55-16:15
16:15-16:35
16:35-17:00
SESSION 10 – TREATMENT EVOLUTION IN TYPE 1 DIABETES
Chairperson
New insulins: Yang Tao, China
The artificial pancreas: Are we there? Moshe Philip, Israel
Beta cell replacement: TBC 
Discussion
17:00
WELCOME RECEPTION